GenesisCare Acquires Ten New ExacTrac Dynamic Systems for Advanced Cancer Treatment Following FDA Clearance

Brainlab to deliver 10 systems to GenesisCare in the US bringing the total investment by the international oncology provider to more than 30 systems globally

Chicago, September 2020Brainlab, the digital medical technology company, announced today the planned delivery of 10 new ExacTrac Dynamic® systems to GenesisCare, offering U.S. cancer patients and physicians access to the latest treatment technologies on the market. This follows GenesisCare‘s acquisition of major integrated cancer care provider,  21st Century Oncology, increasing access to advanced cancer care for patients across U.S. communities.

ExacTrac Dynamic, a patient positioning and position monitoring device, received FDA 510(k) clearance in July 2020 and supports the delivery of precision radiotherapy with surface and thermal tracking combined with real-time X-Ray monitoring. ExacTrac Dynamic will allow GenesisCare physicians to deliver stereotactic radiosurgery, a non-invasive form of radiation therapy which delivers precisely targeted radiation in fewer high-dose treatments than traditional therapies.

Australian-headquartered GenesisCare is one of the largest networks of integrated oncology care in the world, with treatment centers and clinics across Australia, the U.K., Spain and now the U.S. ExacTrac Dynamic systems have already been rolled out in Australia and the UK, providing patients access to the latest advancements in radiation therapy, including stereotactic radiosurgery and tattoo-free treatment.

“During COVID-19, we have remained steadfastly committed to ensuring all cancer patients in local communities across the United States and globally receive rapid access to world-class cancer care. Our investment in these cutting-edge ExacTrac Dynamic systems will help us deliver on our vision to ensure as many cancer patients are able to receive the right treatment, at the right time, closer to home. Our partnership with Brainlab will allow our physicians in the US to automate precise patient monitoring during the delivery of faster, more personalized radiotherapy treatments in our 290 centers across the country,” said Dan Collins, Founder and Global Chief Executive Officer, GenesisCare.

Building upon the first generation ExacTrac X-Ray, the new ExacTrac Dynamic system expands clinical workflows beyond traditional stereotactic capabilities with new surface-guided and thermal technology. These high-precision tracking and verification capabilities enable the delivery of effective prescription target doses, with less radiation to normal healthy tissues, for a wide range of treatment locations in the body. The system allows for:

  • Surface guided patient setup without tattoos or markings
  • Submillimetric patient monitoring using integrated surface, thermal, and X-Ray imaging at all couch angles
  • Real-time motion management with automatic beam-hold enabling future applications such as Deep Inspiration Breath Hold (DIBH) gated treatments*

“It’s exciting for Brainlab to continue to work with GenesisCare as they expand their presence in the United States,” said Stefan Vilsmeier, President and CEO, Brainlab. “We have long partnered with GenesisCare in Australia and the UK and share their vision to make precision radiotherapy more accessible on a global scale.”

First deliveries are planned for November 2020.

To learn more about ExacTrac Dynamic, visit Brainlab.

*ExacTrac Dynamic Receives FDA Clearance and Large Investment from GenesisCare (Source: Brainlab & GenesisCare)

Related articles

Celebrating our GenesisCare Game Changers

Prostate cancer patients from across Peel Region benefit from new specialist nurse

GenesisCare’s Rockhampton centre celebrates half a decade of delivering world-class care to local cancer patients

GenesisCare launches first of its kind brain cancer treatment in Bunbury, drastically reducing treatment times